Over the past 12‑18 months the Blood Bank Gel Card Centrifuges market has accelerated through a series of strategic moves that reshape the competitive landscape. In March 2024, Thermo Fisher Scientific entered a global partnership with BioMérieux to co‑develop a next‑generation centrifuge that integrates real‑time temperature monitoring, targeting high‑throughput hospital labs. The same quarter, Fresenius Kabi completed the acquisition of Swiss‑based Roche Diagnostics' centrifuge division for $210 million, expanding its footprint in Europe and adding a patented low‑vibration rotor technology to its portfolio. July 2024 saw the launch of HelixTech’s “AquaSpin Pro” – a compact, battery‑operated unit designed for mobile blood drives, which complies with the updated FDA 510(k) guidance issued in early 2024 that emphasizes closed‑system safety. Meanwhile, the European Union’s revised In‑Vitro Diagnostic Regulation (IVDR) Class B classification, effective May 2024, has prompted manufacturers to accelerate validation processes. Venture capital activity also surged, with a $45 million Series B round backing CuraFlow to scale its AI‑driven maintenance platform across North America. Collectively, these developments signal a shift toward integrated, portable, and compliance‑focused solutions, underscoring the rapid evolution of Blood Bank Gel Card Centrifuges industry trends.
